Effectiveness of Diabetes Mellitus Type 2 Management in Prolanis Participants at the BPJS Kesehatan Sibolga

BPJS Kesehatan aims to improve the health of participants suffering from Type 2 DM through the Chronic Disease Management Program “Prolanis” (Program Pengelolaan Penyakit Kronis) strategy implemented at Primary Health Care (PHC). Program success is measured by the outcomes of controlled Fasting Bloo...

Full description

Saved in:
Bibliographic Details
Main Authors: ester sitompul, Firdaus Hafidz As Shidieq
Format: Article
Language:Indonesian
Published: BPJS Kesehatan 2024-12-01
Series:Jurnal Jaminan Kesehatan Nasional
Subjects:
Online Access:https://jurnal-jkn.bpjs-kesehatan.go.id/index.php/jjkn/article/view/251
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850033226070884352
author ester sitompul
Firdaus Hafidz As Shidieq
author_facet ester sitompul
Firdaus Hafidz As Shidieq
author_sort ester sitompul
collection DOAJ
description BPJS Kesehatan aims to improve the health of participants suffering from Type 2 DM through the Chronic Disease Management Program “Prolanis” (Program Pengelolaan Penyakit Kronis) strategy implemented at Primary Health Care (PHC). Program success is measured by the outcomes of controlled Fasting Blood Sugar status and the cost-effectiveness of Prolanis. This research was conducted to determine the cost-effectiveness of Prolanis in treating Type 2 DM. Analytical cross-sectional research using secondary data from BPJS Kesehatan in the Sibolga Branch Office work area in 2020-2022 on Type 2 DM participants who took Prolanis and Non-Prolanis. The analysis used univariate, bivariate, multiple logistic regression, and ICER cost analysis. Characteristics of Prolanis participants, age, number of visits, and Body Mass Index showed a significant relationship with the achievement of controlled fasting blood sugar. The average fasting blood sugar of Prolanis and Non-Prolanis participants in 2021-2022 did not significantly differ. Still, the proportion of controlled fasting blood sugar of Prolanis participants was greater than that of Non-Prolanis participants. The total cost of Prolanis in a row for 2020-2022 is IDR 1,437,411,273, IDR 2,706,895,281, and IDR 2,751,510,452. The total cost of Non Prolanis for 2020-2022 is IDR 5,861,773,361; IDR 7,807,455,547,-; IDR 10,291,812,544,-. The ICER for each controlled fasting blood sugar proportion varies from 2020-2022 IDR 462,489; IDR 201,473;  IDR 362,856. Prolanis expenditure at the Sibolga Branch Office is higher, but the clinical effectiveness of the proportion of controlled fasting blood sugar participants is better than that of non-Prolanis participants
format Article
id doaj-art-06a8045c6e8946eb81a3e994d6a3d152
institution DOAJ
issn 2798-7183
2798-6705
language Indonesian
publishDate 2024-12-01
publisher BPJS Kesehatan
record_format Article
series Jurnal Jaminan Kesehatan Nasional
spelling doaj-art-06a8045c6e8946eb81a3e994d6a3d1522025-08-20T02:58:18ZindBPJS KesehatanJurnal Jaminan Kesehatan Nasional2798-71832798-67052024-12-014225126810.53756/jjkn.v4i2.251251Effectiveness of Diabetes Mellitus Type 2 Management in Prolanis Participants at the BPJS Kesehatan Sibolgaester sitompul0Firdaus Hafidz As Shidieq1Gajdah Mada UniversityGajdah Mada UniversityBPJS Kesehatan aims to improve the health of participants suffering from Type 2 DM through the Chronic Disease Management Program “Prolanis” (Program Pengelolaan Penyakit Kronis) strategy implemented at Primary Health Care (PHC). Program success is measured by the outcomes of controlled Fasting Blood Sugar status and the cost-effectiveness of Prolanis. This research was conducted to determine the cost-effectiveness of Prolanis in treating Type 2 DM. Analytical cross-sectional research using secondary data from BPJS Kesehatan in the Sibolga Branch Office work area in 2020-2022 on Type 2 DM participants who took Prolanis and Non-Prolanis. The analysis used univariate, bivariate, multiple logistic regression, and ICER cost analysis. Characteristics of Prolanis participants, age, number of visits, and Body Mass Index showed a significant relationship with the achievement of controlled fasting blood sugar. The average fasting blood sugar of Prolanis and Non-Prolanis participants in 2021-2022 did not significantly differ. Still, the proportion of controlled fasting blood sugar of Prolanis participants was greater than that of Non-Prolanis participants. The total cost of Prolanis in a row for 2020-2022 is IDR 1,437,411,273, IDR 2,706,895,281, and IDR 2,751,510,452. The total cost of Non Prolanis for 2020-2022 is IDR 5,861,773,361; IDR 7,807,455,547,-; IDR 10,291,812,544,-. The ICER for each controlled fasting blood sugar proportion varies from 2020-2022 IDR 462,489; IDR 201,473;  IDR 362,856. Prolanis expenditure at the Sibolga Branch Office is higher, but the clinical effectiveness of the proportion of controlled fasting blood sugar participants is better than that of non-Prolanis participantshttps://jurnal-jkn.bpjs-kesehatan.go.id/index.php/jjkn/article/view/251disease management programprolanisfasting blood sugarcost-effectivenessincremental cost effectiveness ratio
spellingShingle ester sitompul
Firdaus Hafidz As Shidieq
Effectiveness of Diabetes Mellitus Type 2 Management in Prolanis Participants at the BPJS Kesehatan Sibolga
Jurnal Jaminan Kesehatan Nasional
disease management program
prolanis
fasting blood sugar
cost-effectiveness
incremental cost effectiveness ratio
title Effectiveness of Diabetes Mellitus Type 2 Management in Prolanis Participants at the BPJS Kesehatan Sibolga
title_full Effectiveness of Diabetes Mellitus Type 2 Management in Prolanis Participants at the BPJS Kesehatan Sibolga
title_fullStr Effectiveness of Diabetes Mellitus Type 2 Management in Prolanis Participants at the BPJS Kesehatan Sibolga
title_full_unstemmed Effectiveness of Diabetes Mellitus Type 2 Management in Prolanis Participants at the BPJS Kesehatan Sibolga
title_short Effectiveness of Diabetes Mellitus Type 2 Management in Prolanis Participants at the BPJS Kesehatan Sibolga
title_sort effectiveness of diabetes mellitus type 2 management in prolanis participants at the bpjs kesehatan sibolga
topic disease management program
prolanis
fasting blood sugar
cost-effectiveness
incremental cost effectiveness ratio
url https://jurnal-jkn.bpjs-kesehatan.go.id/index.php/jjkn/article/view/251
work_keys_str_mv AT estersitompul effectivenessofdiabetesmellitustype2managementinprolanisparticipantsatthebpjskesehatansibolga
AT firdaushafidzasshidieq effectivenessofdiabetesmellitustype2managementinprolanisparticipantsatthebpjskesehatansibolga